European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials	54
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	54
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?	49
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial	47
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials	44
More knowledge about atrial fibrillation, still we need to learn	44
Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients	43
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	39
Prevention is still the key to success	37
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases	36
Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials	35
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	31
LDL lowering effect of PCSK9 inhibition is reduced in women	31
Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested c	28
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	28
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	27
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	23
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	23
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk	23
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry	23
Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry	23
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19	22
Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors	22
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries	20
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	20

GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity	20
Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases	20
What's new in pharmacotherapy at ESC Congress 2023?	20
Subcutaneous furosemide in heart failure: a systematic review	19
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?	19
Oral anticoagulants and antiplatelet treatment in different settings	19
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?	19
Adherence to pharmacological treatment: how can we improve?	18
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	18
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	18
Thromboprophylaxis for COVID-19-related coagulopathy: what next?	17
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2	17
Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management	17
Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis	17
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure	16
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome	16
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?	16
Fibrates: one more lost paradise in lipid treatment	16
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on	15
Comment on Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	15
Targeting lipoprotein(a): Pharmacotherapy in focus	15
Estimated impact of guidelines-based initiation of dual antihypertensive therapy on long-term cardiovascular outcomes in 1.1 million individuals	15
Lipid treatment	15
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	14
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	14
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	14
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance	14
Cardiovascular risks associated with use of non-steroidal anti-inflammatory drugs in patients with non-obstructive coronary artery disease	14
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics	14
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis	14
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events	13
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	13
Corrigendum to: “2019 guidelines for the diagnosis and management of chronic coronary syndromes”: congratulations and tribulations	13
Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction	13
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain	13
Re: Shahim et al., 2024 “Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction”	12
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis	12
Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground	12
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	12
Incidence and outcomes of transient new-onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	12
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	12
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	11
Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?	11
Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry	11
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	11
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021	11
Letter to the editor in response to Chan et al. 2023	10
Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction: reply	10
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Reg	10
High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation	10

PharmaPulse: new trial evidence from the HFA/ESC Heart Failure Congress 2021	10
Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation	10
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk	10
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19	10
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	9
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA	9
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	9
Proton pump inhibitors: seeking the golden ratio between gastroprotection and cardiovascular risk	9
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry	9
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	9
Pharmacogenetic testing to broaden patient eligibility for mavacamten	9
CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe?	9
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	9
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics	9
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	8
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	8
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	8
Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study	8
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	7
The search for the perfect antiplatelet treatment continues	7
New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021	7
Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials	7
Unsolved pharmacological issues with cardiology	7
Corrigendum to: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	7
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	7
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation	7
Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway	7
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	7
What is new in the 2023 AHA/ACC multisociety guideline on chronic coronary disease?	7
Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)	7
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes—a subgroup analysis of the ISAR-REACT 5 trial	7
Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond	6
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events	6
Non-coding RNA therapeutics in the treatment of heart failure	6
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?	6
Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study	6
Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC–EHRA EORP AF Long-Term General Registry	6
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases	6
Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome	6
The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease	5
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial	5
Renal protection in chronic heart failure: focus on sacubitril/valsartan	5
Pre-treatment with P2Y12 inhibitors in Acute Myocardial Infarction with Cardiogenic Shock	5
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	5
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial	5
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	5
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	5
Reducing the risks of nuclear war: the role of health professionals	5
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consens	5
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study	5
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle	5
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension	5
European Heart Journal—Cardiovascular Pharmacotherapy to become fully open access in 2025	4
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	4
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis	4
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis	4
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies	4
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care	4
EHJCVP Reviewers 2022	4
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines	4
Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial	4
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study	4
Call for emergency action to limit global temperature increases, restore biodiversity, and protect health	4
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	4
Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiol	4
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	4
The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials	4
Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction	3
Advances in the understanding of excitation-contraction coupling: the pulsing quest for drugs against heart failure and arrhythmias	3
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking	3
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	3
Low-dose aspirin and incident atrial fibrillation in healthy older individuals: a post-hoc analysis of the ASPREE trial	3
Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study	3
Statin therapy reduces dementia risk in atrial fibrillation patients receiving oral anticoagulants	3
A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study	3
Pharmacological treatment of CVD	3
Future of European Heart Journal Cardiovascular Pharmacotherapy	3
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	3
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?	3
RNA-targeted therapeutics in cardiovascular disease: the time is now	3

Cardiovascular preventive actions	3
Vericiguat in the management of heart failure with reduced ejection fraction	3
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	3
Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes	3
Focus on optimizing treatment of coronary heart disease	3
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	3
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	3
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention	3
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis	3
Updates from the American Heart Association Scientific Sessions: cardiovascular pharmacotherapy	3
Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes?	3
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinic	3
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation at low risk of stroke in japan: a retrospective cohort study	2
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	2
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	2
CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction	2
The revolution in pharmacotherapy: from herbs to pills, moulds, antibodies to genetic tools	2
New ways of mitigating aldosterone in cardiorenal disease	2
All about clinical trials	2
Prescribing trends of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction	2
Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention	2
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis	2
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	2
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study	2
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis	2
P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting	2
Unexplored horizons on sex bias and progression of heart failure with preserved ejection fraction	2
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	2
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	2
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and netwo	2
Trial-level surrogacy of non-high-density and low-density lipoprotein cholesterol reduction on the clinical efficacy of statins	2
Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence	2
To treat or not to treat	2
OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold	2
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	2
A tailor-made suit always fits best	2